C-1101
Phase 1Small molecule
C-1101 is one of 11 small molecule programs targeting Radiculopathy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Radiculopathy
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Trental
VValidus Pharmaceuticals
Approved
Advil
KKenvue Brands
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marcaine
IInnocoll
Approved
Kenalog
BBassett Healthcare
Approved
Catapres
Boehringer IngelheimPreclinical
Aristospan
EEthypharm
Preclinical
C-1101
CConsano Bio
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for C-1101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CConsano Bio